27 February 2008
ORLANDO, FL, February 27, 2008 – As part of its global program to encourage continuing education and research in the field of veterinary internal medicine, Intervet International, a part of Schering-Plough, sponsored a full day program on endocrinology under the American Board of Veterinary Practitioners (ABVP) at the North American Veterinary Conference (NAVC) in Orlando (USA).
The 2008 NAVC (North American Veterinary Conference) congress was held from January 19 to 23, 2007 in Orlando, Florida, USA. Once again, this congress was remarkably successful in terms of participation and remains one the most renowned veterinary events of the year with more than 15,000 participants.
As one of the largest animal health companies in the world, Intervet holds a leading position in veterinary endocrinology with products such as VETSULIN®* (porcine insulin zinc suspension) - for the treatment of diabetes mellitus in dogs - and LEVENTA® (levothyroxine sodium) – for the treatment of hypothyroidism in dogs. As part of its global program to encourage continuing education, Intervet sponsored a full day program on veterinary endocrinology in collaboration with the American Board of Veterinary Practitioners (ABVP).
The lectures were presented by Dr. J Catharine Scott Moncrieff (School of Veterinary Medicine, Purdue University) and Dr. Joseph Taboada (Louisiana State University, School of Veterinary Medicine). The topics covered a wide range of subjects including: update on insulin therapy, diagnostic approach to hypoglycemia in dogs, challenging endocrine cases, management of diabetic ketoacidosis, and more. More than 1700 practitioners attended these lectures.
The endocrinology day was a great success both in terms of the quality of the lectures and the number of attendees. “Intervet International is proud to be associated with the NAVC congress and looks forward to continue to support international scientific events as part of its dedication in support of companion animal internal medicine”, says Hubert Trentesaux, head of Global Companion Animal.
This sponsored day was one of the many events organized by the Schering-Plough Animal Health and Intervet teams. Intervet and Schering-Plough are combining efforts to bring to the companion animal community a flow of science-based solutions and services as a promise of our combination: “Together for Better Care”.
*Vetsulin is marketed outside the U.S. as CANINSULIN®. CANINSULIN is approved for the treatment of diabetes mellitus in cats in several countries, excluding the U.S.
---
Note for the editor
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its website is www.schering-plough.com.”
For more information about Intervet visit the following website: www.intervet.com
Intervet is a leader in research and dedicated to the development, production and marketing of innovative, high-quality animal-health products, such as Continuum®, Vetsulin®, Panacur®, Leventa® and more. For more information visit the following Web sites: www.Intervetusa.com and www.Vetsulin.com, www.Leventa.com
Continuum, Vetsulin, Panacur, Leventa and Caninsulin are registered trademarks of Intervet Inc. or an affiliate.
© 2008 Intervet Inc. All rights reserved.
